1. Liver fibrosis is closely linked with metabolic-associated diseases in patients with autoimmune hepatitis.
- Author
-
Liu K, Feng M, Chi W, Cao Z, Wang X, Ding Y, Zhao G, Li Z, Lin L, Bao S, and Wang H
- Subjects
- Humans, Male, Female, Cross-Sectional Studies, Middle Aged, Adult, China epidemiology, Non-alcoholic Fatty Liver Disease pathology, Non-alcoholic Fatty Liver Disease complications, Biopsy, Severity of Illness Index, Risk Factors, Metabolic Diseases complications, Hepatitis, Autoimmune complications, Hepatitis, Autoimmune pathology, Liver Cirrhosis pathology
- Abstract
Background: This cross-sectional study aimed to investigate the impact of metabolic-associated diseases (MADs) on patients with autoimmune hepatitis (AIH)., Methods: The study analyzed the clinical characteristics of 283 AIH patients who underwent liver biopsy between January 2016 and February 2022 in Ruijin Hospital, Shanghai, China., Results: Among the identified AIH patients (n = 283), 87.3%, 23.0%, or 43.1% had MADs, non-alcoholic fatty liver disease (NAFLD), or severe fibrosis, respectively. The proportion of diabetes mellitus (DM) was significantly higher in patients with severe liver fibrosis than in those with mild or moderate fibrosis in the AIH cohort (31.1% vs. 18.0%, p < 0.05). Fibrosis was also more severe in patients with NAFLD than in those without (53.8% vs. 39.9%, p < 0.05). Age, Plts, IgG and the presence with MADs were identified as independent predictors of the severity of inflammation in AIH patients. Moreover, severe liver fibrosis (stages 3 to 4) was independently associated with male (OR, 2.855; p = 0.025), γ-GT (OR, 0.997; p = 0.007), and combination with MADs (OR, 4.917; p = 0.006). Furthermore, combination with DM was also an independent predictor of severe liver fibrosis in AIH patients (OR, 2.445, p = 0.038)., Conclusions: Concurrent MADs, common in AIH patients, is an independent risk factor for severe fibrosis or inflammation; of note, combination with DM was also an independent predictor of severe liver fibrosis in AIH patients. While managing with AIH, routine assessment of co-existing MADs, especially DM, is also important., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF